MedPath

Two is Better Than One: A Novel Venous Access System for Intermittent Apheresis

Completed
Conditions
Apheresis
Interventions
Device: PowerPort
Registration Number
NCT04846374
Lead Sponsor
University of North Carolina, Chapel Hill
Brief Summary

Purpose: To describe a novel configuration of venous access for the performance of intermittent apheresis.

Participants: 20 participants at UNC who were referred for change from a vortex port to a powerflow port.

Procedures (methods): Placement of one of two configurations of the powerflow port and follow up visits between January 1, 2019 and December 31, 2023.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Over the age of 18 years of age.
  • Referred for change from a vortex port to a powerflow port.
  • Previously placed or scheduled placement of one of two configurations of the PowerFlow port
Read More
Exclusion Criteria
  • Unable to read and understand English.
  • Unable to provide informed consent.
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
PowerPort SubjectsPowerPortThis study will involve a chart review of patients at UNC who were referred for change from a vortex port to a powerflow port.
Primary Outcome Measures
NameTimeMethod
Change in Flow Rate1 year following new port configuration placement

The study will compare mean change flow rate for pheresis sessions with the old system versus pheresis sessions with one of two new configurations by averaging the flow rate for up to 5 sessions using the new port configuration.

Change in Procedure Time1 year following new port configuration placement

The study will compare mean change in procedure time for pheresis sessions with the old system versus pheresis sessions with one of two new configurations.

Secondary Outcome Measures
NameTimeMethod
Change in Use of Tissue Plasminogen Activator1 year following new port configuration placement

The study will compare mean change in use of tissue plasminogen activator for pheresis sessions with the old system versus pheresis sessions with one of two new configurations.

Trial Locations

Locations (1)

University of North Carolina at Chapel Hill

🇺🇸

Chapel Hill, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath